Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation

Area of Science:

• Immunology
• Neuroimmunology
• Cell Biology

Background:

• Interferon beta (IFNbeta) is a therapeutic for multiple sclerosis (MS), reducing relapse rates and disease activity.
• The precise molecular mechanisms underlying IFNbeta's therapeutic effects in MS remain largely unknown.
• Dendritic cells (DCs) play critical roles in immune responses and are implicated in autoimmune diseases like MS.

Purpose of the Study:

• To investigate the effect of IFNbeta on myeloid dendritic cell (DC) viability and apoptosis.
• To elucidate the molecular pathways involved in IFNbeta-induced DC apoptosis.
• To explore the potential therapeutic implications of IFNbeta's effect on DCs in MS.

Main Methods:

• Treatment of mature and immature myeloid DCs with exogenous IFNbeta or stimulation with lipopolysaccharide (LPS) to induce endogenous IFNbeta.
• Assessment of DC apoptosis using caspase activation assays (caspase-3, caspase-11).
• Analysis of signaling pathways including NF-kappaB and STAT-1 activation.
• In vivo studies in wild-type (wt) and STAT-1-deficient mice following LPS administration.

Main Results:

• IFNbeta induced apoptosis specifically in mature myeloid DCs, not immature ones.
• DC apoptosis required activation of both NF-kappaB and STAT-1 signaling pathways.
• The apoptotic process was mediated by the induction of caspase-11 and subsequent activation of caspase-3.
• In vivo, LPS administration led to increased caspase-11 expression and reduced splenic DC numbers in wt mice, but not in STAT-1-deficient mice.

Conclusions:

• IFNbeta eliminates mature, activated myeloid dendritic cells through a caspase-11-dependent pathway.
• This IFNbeta-mediated DC apoptosis, dependent on NF-kappaB and STAT-1, may contribute to immune homeostasis.
• The findings suggest a novel molecular mechanism for IFNbeta's therapeutic efficacy in multiple sclerosis.